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Abstract 
Dramatic advances in genomics and rapid progress in the Human Genome Project 
have resulted in a vast number of therapeutic targets available to researchers in traditional 
pharmaceutical and biotech companies that aim to join or serve the pharmaceutical 
industry. Consequently, the total number of new drug projects and the expenditure of 
research and development (R&D) worldwide have increased dramatically in this decade.  
However, despite the rising efforts (time and money) in the industry, the actual number of 
new drugs that reached the markets is declining year by year. To reveal the significance 
of strategic alliance to the value chain of biotech and pharmaceutical (bio/pharma) 
industry, this report reasons the demand of external R&D resources in the present 
circumstances through reviewing literature of bio/pharma R&D collaboration and recent 
news of the restructuring in this sector. This report further identifies the advantages and 
disadvantages of strategic alliances to bio/pharma firms by comparing with other 
transactions, such as mergers and acquisitions and licensing.  
In the circumstances of the globalizing drug market, Western bio/pharma firms 
are faced with strong challenges by confining their businesses to domestic markets. In 
addition, as many developing countries now have the honed skills and knowledge in drug 
discovery and development, intense competition now comes from all over the world. The 
later part of this report thus aims to discover whether Western bio/pharma companies 
could strengthen their competitiveness through the R&D collaboration with those in 
developing countries (the case of Asia). By detailing the biotech promoting policies and 
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incentives, the development of human capital and the overall bio/pharma environment in 
China, India, Singapore and Taiwan, this report provides a comprehensive analysis of 
opportunities and threats to Western bio/pharma companies through the Western-Asian 
partnerships. Finally, in light of the complex value chain of drug development, this report 
presents the different specialties of these Asian countries and suggests the most 
functional and profitable types of collaboration for the Western bio/pharma companies. 
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Glossary 
bio/pharma In this report, it refers to traditional pharmaceutical and pharmaceutical-oriented biotech companies  
BLA (Biologics License 
Application) 
With the same purpose as NDA, but for biologic products 
CDER (Center for Drug 
Evaluation and Research) 
A division of the U.S. Food and Drug Administration (FDA) that 
ensures drugs are safe and effective 
cGMP (current Good 
Manufacturing Practice) 
Regulations promulgated by FDA for the control and 
management of manufacturing and quality control testing of 
foods, pharmaceutical products, and medical devices. 
CRO (Contract Research 
Organization) 
A service organization that provides supports from preclinical to 
clinical R&D to the pharmaceutical/biotech industry 
DOH (Department of 
Health) 
In this report, it refers to the Taiwanese government department 
responsible for public health issues 
FDA (Food and Drug 
Administration) 
An agency of the United States Department of Health and Human 
Services; responsible for regulating and supervising the safety of 
foods, dietary supplements, drugs, vaccines, biological medical 
products, blood products, medical devices, radiation-emitting 
devices, veterinary products, and cosmetics. 
GDP (Gross Domestic 
Product) 
A basic measure of an economy's economic performance 
IBD (Irritable Bowel 
Syndrome) 
A functional bowel disorder characterized by chronic abdominal 
pain, discomfort, bloating, and alteration of bowel habits in the 
absence of any organic cause 
ICH (International 
Conference on 
Harmonization) 
A unique project that brings together the regulatory authorities of 
Europe, Japan and the United States and experts from the 
pharmaceutical industry in the three regions to discuss scientific 
and technical aspects of product registration 
  
  xi
GCP (WHO Good Clinical 
Practice) 
The WHO guidelines to set globally applicable standards for the 
conduct of biomedical research on human subjects, such as 
clinical trials 
in vitro The technique of performing a given procedure in a controlled environment outside of a living organism. 
IND (Investigational New 
Drug) application 
The means by which a drug sponsor obtains permission to ship an 
experimental drug across state lines (usually to clinical 
investigators) before a marketing application for the drug has 
been approved 
IP (Intellectual Property) Legal property rights over creations of the mind, both artistic and commercial, and the corresponding fields of law 
LDL (Low Density 
Lipoprotein) 
So-called “bad cholesterol”, high levels of LDL cholesterol can 
signal medical problems like cardiovascular disease 
M&A (Merger and 
Acquisition) 
The aspect of corporate strategy, corporate finance and 
management dealing with the buying, selling and combining of 
different companies 
MS (Multiple Sclerosis) 
A neurological autoimmune disease; the symptom often 
progresses to physical and cognitive disability and 
neuropsychiatric disorder. 
NCE (New Chemical Entity) 
A drug that contains no active moiety that has been approved by 
FDA in any other application submitted under section 505(b) of 
the Federal Food, Drug, and Cosmetic Act 
NDA (New Drug 
Application) 
An application proposed by drug sponsors, providing sufficient 
information about manufacturing process and the result of clinical 
trials of drug candidates to endeavour FDA approval for sale and 
marketing  
Recombinent DNA 
technology 
The technology used to create a form of DNA that does not exist 
naturally  by combining DNA sequences that would not normally 
occur together 
TB (Tuberculosis) 
A common respiratory infectious disease; usually cause a chronic 
cough with blood-tinged sputum, fever, night sweats, weight loss 
or even death 
VC (Venture Capital) 
A type of private equity capital typically provided to early-stage, 
high-potential, growth companies in the interest of generating a 
return through an eventual realization event such as an IPO or 
trade sale of the company 
  xii
WHO (World Health 
Organization) 
The directing and coordinating authority for health within the 
United Nations system; responsible for global health matters 
WTO (World Trade 
Organization) 
The only global international organization dealing with the rules 
of trade between nations 
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Chapter 1 Overview 
In the regime of rapid technological development, research breakthroughs are so 
broadly distributed that a single firm can hardly have all the internal capabilities required 
for success in innovation. Previous literature indicates that inter-firm alliance has become 
a common strategy in many industries in recent decades. Particularly in those sectors that 
heavily rely on technology, the use of alliances is an important strategy to create 
economic scale, facilitate resource sharing, learn new skills and technologies, reduce 
risks, and expand market coverage. Broadly, strategic alliances refer to inter-firm 
collaboration aimed at achieving a firm’s strategic objectives (Yoshino & Rangan, 1995). 
In the biotechnology (biotech) and pharmaceutical (pharma) industries where the 
knowledge base is both complex and expanding and the sources of expertise are widely 
dispersed, the locus of innovation can be found in networks of learning, rather than in 
individual firms. Additionally, it is barely possible for a research-oriented firm to 
complete the time-consuming and costly process of drug discovery and development all 
along. This process includes the elaborate preclinical and clinical R&D, manufacturing, 
marketing and distributing activities, which make the final products delivered to the 
consumers. As a result, intense collaboration within the biotech and pharma industries 
appears on many levels including horizontal partnership such as research partners among 
firms, or distributing and marketing team-ups, and vertical partnership among academic 
research institutes, biotech and pharma firms (Edwards, Murry, & Yu, 2003; Stuart, 
Ozdemir, & Ding, 2007). While there are benefits for firms to exploit strategic alliances, 
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studies showed that reliance on external partners involves potential hazards (Powell, 1990; 
Sabel, 1993). The complexity of a joint project, difficulties in relinquishing control and a 
lack of trust between the parties are all barriers to collaboration. As opposed to 
contractual relationships, the alternative would be to create an internal mode for research 
and development. It is evident that the traditional pharmaceutical firms mostly have bulky 
in-house research units, but recent news and studies all show that the vertical R&D 
partnership actually provides substantial benefits to pharmaceutical firms. In short, when 
the strategic alliances can provide more opportunities than threats, firms turn to 
collaboration to acquire resources and skills they cannot produce internally. 
At the present time, “globalization” has had a critical impact on the economy. It 
first appeared in the 1960s and has been used to define a transformation process that 
accelerated in the 1980s. In this context, free-market economy, privatization, and 
liberalization are the main characteristics of globalization. Globalization, however, can 
also be viewed as a process aimed at increasing the growth and widespread distribution of 
capital. During this process, globalization has destroyed values and rules that do not serve 
its aims (Semin & Guldal, 2008). Globalization has also affected the pharmaceutical 
industry and caused serious and inevitable contradictions and conflicts. There is no easy 
way to measure the effect of globalization on the pharmaceutical sector in terms of 
production, trade, prices, profit, and consumption, as there are variations in social 
divisions in terms of classes and countries. As a result, several studies have discussed the 
motives and management of cross-border R&D alliances, such as absorptive capacity, 
technology learning and partner selecting (Appleyard, Lybecker, & Wang, 2008; Kim & 
Inkpen, 2005). 
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When talking about the globalization and cross-border strategic alliances, it is 
indispensable to study the role that Asian developing countries play under the 
circumstances. The emerging market economies of Asia remain a bright spot in the global 
picture, particularly in China and India. According to the World Factbook of the US 
Central Intelligence Agency, the Gross Domestic Product (GDP) - real growth rates were 
over 5% for both countries during the 2008 economic downturn (Central Intelligence 
Agency, July 2009). Besides the overall economic growth in the Asian countries, the 
whole pharmaceutical and biotechnology sector there is booming, including both R&D 
techniques and the pharmaceutical market. Considering this emerging business in Asia, as 
well as the well-established one in the Western developed countries (especially the 
United States), it seems a good opportunity to expand this industry into a global scope 
through the strategic alliances between Western (North American & European) and Asian 
pharmaceutical and biotechnology companies. In fact, several companies have already 
built collaboration in different stages of the drug discovery process. For example, aiming 
to become a global biomedical sciences hub, Singapore has attracted both the 
multinational pharmaceutical and small-medium biotech companies to build partnerships 
with domestic biotech companies.  
This report presents the know-how of strategic alliances and the status quo of the 
Asian biotechnology and pharmaceutical industry, and provides an analysis of business 
opportunities and threats to the Western firms that plan for, or never think of, the 
Western-Asian collaboration. The structure of this report is as follows: Chapter 2 
provides an introduction of pharmaceuticals and the drug discovery & development 
process,  the differences between traditional and biotech pharmaceuticals, and the 
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timeline and expenditures of the conversion from biological molecules to medicines. 
Chapter 3 focuses on the reasons of recent restructure in the sector analyzing the urgent 
demand for external R&D resources, the advantages and disadvantages of strategic 
alliances and the trend of R&D alliances toward a global scale. IChapter 4 narrows down 
the geographic area to the Asian arena, analyzing the business opportunities and threats 
of the strategic alliances for Western-Asian pharmaceutical and biotechnology companies.  
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Chapter 2 Introduction of Bio/Pharma Industry 
2.1 Traditional vs. biotechnology pharmaceuticals 
Drugs are substances that affect the functions of living things and are 
administered to treat, prevent, or cure unwanted diseases and symptoms. The sacrosanct 
mission of medicine to cure illness, as well as the distinctive value chain of this industry, 
makes the business of pharmaceuticals alluring and indispensable.  
With the different chemical characteristics and the unlike discovering and 
manufacturing process, pharmaceuticals are generally sorted into small-molecule drugs 
(traditional drugs) and biotech drugs. As implied by the name, biotech drugs are proteins 
(big molecule) that are discovered and produced through the recombinant DNA 
technology or other burgeoning biotechnology. The first biotech drug in the history is the 
bacteria-synthesized recombinant human insulin for the treatment of diabetes from 
Genentech, which was established in 1976 as the first biotech company in the world 
(Friedman, 2006). Prior to the advent of molecular biology techniques, traditional 
pharmaceutical development is limited to chemical synthesis. Therefore, the drugs that 
are produced by traditional pharmaceutical means tend to be small molecules (or 
chemical entities) and usually oral-taken as pills (Friedman, 2006). 
Considering the nature of biotech drug development is heavily based on scientific 
knowledge to either design drugs from scratch or develop a rational method to identify 
and modify existing compounds, drug discovery is no longer exclusive to big 
pharmaceutical companies (Big Pharma), but contributed by many research- intensive 
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biotech companies as well. In the following sections, “bio/pharma” is used to embrace the 
drug development-oriented biotech companies and traditional comprehensive 
pharmaceutical companies.  
2.2 Drug Discovery & Development 
In the process of drug development, drug candidates are identified and subjected 
to increasingly stringent tests to determine if they are safe and effective. In the United 
States, the effective drug candidates will eventually be examined by The Food and Drug 
Administration (FDA), who regulates drug marketing, requiring manufacturers to prove 
their products to be safe, effective, and appropriately labeled, before gaining approval. 
The standards of evidence for new drug approval are similar across countries. For 
example, the three largest prescription drug markets in the world, including the United 
States, the European Union and Japan, have taken steps to harmonize their procedures to 
ensure the timely introduction of new drugs and to reduce the cost of development.  
Like those in other high-tech industry, the process of producing and selling drugs 
consists of three basic stages: discovery, development and commercialization. However, 
as the products of bio/pharma industry are meant for human therapeutic use, it takes the 
manufacturer an average of 14 years to develop a drug. The process below, as shown in 
Figure 2.1, demonstrates why drug development is so labor-intensive, time-consuming 
and expensive. 
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2.2.2 Preclinical R&D 
Once the potential drug that works in a model system is identified, it is time to 
study the pharmakinetics and other properties of the drug candidates in the in vitro 
system. The potential drug that works in an in vitro model system is called a lead 
compound and further tested on animal models. While many studies argue that the 
success in animal tests does not necessarily suggest that a lead compound will work in 
humans, animal test so far is the only real way to determine whether the lead compound 
is effective and safe enough to try on humans. More importantly, through animal studies, 
researchers can establish the method of administration that makes the substance end up in 
the right place in the bodies contribute to ensure the optimal effect.  
After the efficacy of the drug candidate is proved, the compound, and maybe the 
manufacturing procedures, is likely protected by a patent that extends 20 years from the 
date of the patent application. Although the innovation process in bio/pharma industry is 
similar with that in other high-tech sector, it is shown that at least 100 research projects 
could eventually lead to only one drug on the market. Because of the difficulties for 
preclinical research to become a drug, the gap between the traditional finishing point of 
research supported by an academic grant, and the sort of programs industry is interested 
in licensing or venture capitalists are prepared to back through a startup is usually called 
as “the valley of death” (Moran, 2007). 
 
2.2.3 Clinical R&D -- Phase I, II, III Trials 
Until now, all research has been conducted outside human bodies. However, no 
one can ensure whether the drug candidate can be delivered correctly and against the 
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human diseases, as the way it worked in the animal model. The answer of the question 
comes from years of researches in thousands of patients and healthy people. In order to 
pursue human studies, the first criterion is that the drug candidate must be produced 
under current good manufacturing practices (cGMP). Secondly, a sponsor must first 
submit an Investigational New Drug (IND) application to the FDA to justify testing a 
drug in humans. There are four phases of clinical trials. Phases I through III is to 
demonstrate safety and efficacy prior to approval, whereas Phase IV is to monitor safety 
post-approval and tests new treatment indications. The function of each stage in the 
clinical trial is discussed below.  
PHASE I TRIALS 
Beyond the purpose of finding the component that treats disease effectively, the 
primary consideration in drug discovery process ought to be the safety of the medicine 
takers. The Phase I trial is usually conducted in a small group (20-50) of normal, healthy 
volunteers to determine the safe dosing range and toxicity of a compound and study the 
clinical pharmacological mechanism, such as drug absorption, distribution and metabolite 
in human bodies. This phase usually takes an average of one to three years. Once Phase I 
trials do not reveal unacceptable toxicity, it is allowed to proceed to Phase II trial. 
PHASE II TRIALS 
The purpose of Phase II trial is to further evaluate a drug’s safety, assess side 
effects, and establish dosage guidelines. The well-controlled experiment is usually  
conducted on a larger number of volunteers (about 100 to 300 patients), who have the 
medical condition that the product is intended to treat, in order to establish the range of 
minimal effective dosage, maximum tolerable dosage, and optimal dosage. Phase II trial 
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usually takes an average of two years. If Phase II trials indicate effectiveness, a drug can 
proceed to Phase III trials. Generally, a drug that moves on to Phase III trials has an 
approximately 60 percent chance of being approved by the FDA. 
PHASE III TRIALS 
Phase III is the largest and most expensive stage in the clinical trials. The purpose 
of Phase III trial is to continue the development of safety profile and the record of 
possible side effects and adverse reactions that result from long-term use. Phase III trial is 
a tightly controlled, and preferably double-blind, study that is usually conducted on at 
least 1,000 patients. In double-blind studies, neither patients nor the individuals treating 
them know whether the active drug or an alternative such as placebo is being 
administered. Compared to Phase I and Phase II trials, the larger and ideally more diverse 
populations used in Phase III trial are necessary to determine the condition where certain 
types of patients develop side effects or do not respond to treatment. Two successful 
Phase III trials are usually required to ensure the validity of the studies. The whole 
process usually takes an average of three to four years. 
Overall, the process of clinical trials is a considerable challenge to potential drugs. 
Rushing each stage may require the entire repetition or lead to outright failure. It also 
takes vast amount of money and an average of 6.5 years to carry out three phases of 
clinical trials. Once a drug reaches the desirable end point in Phase III trials, the result of 
all stages will be filed a New Drug Application (NDA) or Biologics License Application 
(BLA) which are then assessed by the health organizations that decide whether to 
approve or reject the marketing of the drugs.  
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2.2.4 NDA and BLA Review & Approval 
NDAs describe small molecule therapeutics, whereas BLAs cover therapeutics 
applications of big molecule such as antibodies, growth factors and protein-based drugs. 
Both applications are submitted to the Center for Drug Evaluation and Research (CDER). 
Following NDA/BLA submission, a drug has a better than 70 percent chance of being 
approved. However, approval of an application can take anywhere from two months to an 
extreme of several years, if the FDA requests additional information. Fortunately, the 
Hatch-Waxman Act permits day for day recovery of patent life for time spent waiting for 
FDA approval (Federal Trade Commission, 2002, pp. 3-8). Following FDA approval, a 
company may market and distribute a drug to the patient population determined in Phase 
III trials. At this point, the lifespan of the patent that was filed sometime before clinical 
trials began often ranges from 8 to 12 years. After that, the patent protection will expired, 
and the numerous entries of generic manufacturing companies decrease the profit margin 
of the drug. 
On the other hand, the cases of disapproval usually come from the inauthentic 
discussion in the applications to FDA. The company with the disapproved drug can 
decide whether it is worth running new trials and seeking approval again. Alternatively, 
the company can sell it to another company, or ally with a partner to share the risk and 
future revenue. 
 
2.2.5 Drug on the Market & Phase IV 
Phase IV trial is also known as Post Marketing Surveillance Trial. As the drug on 
the market would be prescribed to larger and more diverse populations, the company 
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must continue to perform observational studies in an ongoing evaluation of the drug’s 
safety during routine use. The safety surveillance is designed to detect any rare or long-
term adverse effects over a much larger patient population and longer time period than 
was possible during the Phase I to III clinical trials. Harmful effects discovered by Phase 
IV trials may result in a drug being no longer sold, or restricted to certain uses: recent 
examples involve Baycol and Lipobay from Bayer AG (Barmen, Germany), Rezulin from 
Daiichi Sankyo Co.(Tokyo, Japan) and Vioxx from Merck (New Jersey, US) (Bayer 
Corporate Investor Relations, 2001; Johnson & Winslow, 2008). 
In summary, the combination of long lead-times from discovery to NDA/BLA 
approval, the high probability of failure for drug candidates entering clinical testing, and 
the unpredictability of sales once a product is marketed creates a risky business 
environment. Decisions to fund clinical trials are critical to economic success, and the 
stakes increase substantially as drug candidates move through each successive clinical 
phase. Due to the frequent licensing transactions and alliances throughout the drug 
discovery process, it is complicated to sum up the total expenditure on drug discovery. 
According to the study entitled “The price of innovation: new estimates of drug 
development costs”, the average capitalized costs of bringing a new drug, or more 
precisely a new chemical entity (NCE), to market was US$ 802 million in 2000 dollars, 
while some studies argue that the estimate was likely to be conservative (DiMasi, Hansen, 
& Grabowski, 2003; Frank, 2003).  
Considering the distinct nature and manufacturing process of chemical entity from 
biologic drug, the cost of an approved biopharmaceutical would be different. Some argue 
that biologics are less costly to develop because bio/pharma firms need to be more nimble 
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and creative or that fewer safety issues arise for many biologics because they replace 
substances that exist naturally in the body. However, some industry insiders estimate that 
the cost per approved biologic drug exceed $1 billion (DiMasi & Grabowski, 2007). The 
study named “The cost of Biopharmaceutical R&D: Is biotech different?” shows that the 
estimated total capitalized cost per approved biologic was about US$1241 million in 
2005 dollars. Adjusted by the past growth rates for pharmaceutical company costs, the 
cost was nearly the same as that of a new chemical entity -- US$1241 million versus 
US$1318 million in 2005 dollars (DiMasi & Grabowski, 2007). Once the drug is 
approved and released into market, the major revenue comes from the price and sales 
volume of the drug. Therefore, to ensure a certain payoff, bio/pharma firms usually need 
to expend another huge cost of marketing and distribution.  
On the other hand, given the patent protection, the bio/pharma company usually 
can monopolize the market of the medicine, resulting in the emergence of blockbuster 
drugs (drugs that generate more than US$1 billion of revenue for its owner per year). As 
shown in Table 2.1, the payoffs of the leading blockbuster drugs were billions of US 
dollars per year (EvaluatePharma, 2008; Wikipedia, July 2009). The high up-front cost 
and the lion’s share of investment, turnover and sales, combined with the necessity of 
medicine, make the bio/pharma an interesting, risky and indispensible industry 
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Table 2.1     The annual sales of leading blockbuster drugs 
Trade name/ Medication  Company 
Sales 
(USD in billions) 
Year 
Lipitor (atorvastatin)  Pfizer  12  2007 
Plavix (clopidogrel) 
Bristol‐Myers Squibb and 
sanofi‐aventis 
5.9  2005 
Lovenox/Clexane (enoxaparin)*  sanofi‐aventis  3.5  2007 
Nexium (esomeprazole)  AstraZeneca  3.3  2003 
Losec/Prilosec (omeprazole)  AstraZeneca  2.6  2004 
Celebrex (celecoxib)  Pfizer  2.3  2007 
Telfase/Allegra (Fexofenadine)  Aventis  1.87  2004 
Seroquel (quetiapine)  AstraZeneca  1.5  2003 
Seloken/Toprol (metoprolol)  AstraZeneca  1.3  2003 
Pulmicort/Rhinocort 
(budesonide) 
AstraZeneca  1.3  2003 
Source: Wikipedia, July 2009 
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Chapter 3 Strategic R&D Alliances in the Globalizing 
Bio/Pharma Industry 
As discussed in the previous chapter, it is unlikely for a Big Pharma to complete 
the process through drug discovery to marketing all alone, not to mention the smaller 
bio/pharma companies. From the constant restructuring and transaction, the need of 
external R&D resources in the bio/pharma industry seems very straightforward. However, 
due to the multifarious operational activities, literature usually focuses on a part of drug 
discovery chain. In the following section, the demands and reasons of bio/pharma 
companies’ strategic R&D alliances are analyzed based on recent news and studies. 
3.1 The demand of bio/pharma companies’ strategic R&D alliances 
3.1.1 Expending the early-stage R&D resources 
As the progressive discovery in the human genomics and molecular biology, the 
number of identified pathological mechanisms and factors has increased dramatically in 
these decades. To dig out the potential therapeutic targets and develop drugs, not only Big 
Pharmas have expanded their R&D departments, but also more and more start-up 
bio/pharma companies holding their research expertise have committed themselves to 
new drug discovery. According to the information from consulting firm Frost & Sullivan 
(New York, USA), as cited in Gwynne (2002), the US bio/pharma companies held around 
75,000 new drug projects in the year of 2002. It suggests that the bio/pharma industries 
had vital R&D activities and attempted to increase the efficiency and productivity of drug 
discovery at that time.  
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However, as the saying goes, “the lower hanging fruits would be picked sooner.” 
The process of new drug discovery now is not always as smooth as that was decades ago. 
According to the data from the Centre for Medicines Research International, a business of 
Thomson Reuters information company (New York, USA), while both the averages of 
global R&D expenditure and development time were increasing, the number of new 
drugs that reached the market actually declining year by year. In 2007, the amount of new 
molecular entity (NME) output was only 50% of that in 1997 (Figure 3.1; Harris, 2009). 
In the circumstances, the in-house R&D facility of the bio/pharma companies is no longer 
efficient or productive enough to full up their pipelines -- the lifeblood of bio/pharma 
companies. In other words, bio/pharma companies need the external R&D resources to 
enhance their competitiveness.  
 
Figure 3.1     Global R&D expenditure, development times and new molecular entity 
output (1997‐2007) 
Sources: Centre for Medicines Research International, as cited in Harris, 2009 
 
During the 2008 economic downturn, it was surprising that many Big Pharmas 
had goodish financial performance. Pfizer, for example, showed only 0.2% decrease in 
revenues and 0.4% decrease in net income (Pfizer Inc., 2008). Likewise, although Merck 
had a 1.4% decrease in revenues, its net income in 2008 was actually twice as much as 
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that in 2007 (Merck & Co., Inc., 2008). The attractive figures of their net income, 
however, do not mean that these Big Pharmas were not affected by the bad economy. In 
fact, in the latter part of 2008, many companies cut down the expenses from the sales 
facilities and in-house R&D teams. For example, through the broader company-wide 
restructuring plan that caused the major part of the doubled net income, Merck cut 6,800 
employees and 400 vacant positions in all areas of the company. The large scale layoff 
was listed as the top 5 layoffs of 2008 (Martino, 2008). As it is said, “an evil chance 
seldom comes alone,” during the JP Morgan event, Pfizer laid off 800 of its R&D 
researchers in a tacit admission that its laboratories have failed to live up to the tens of 
billions of dollars it has poured into them in recent years (Rockoff, 2009). As shown in 
Figure 3.2, the number of the bio/pharma layoffs has kept above 15,000 per year since 
2003 (Simon, 2007).  
 
Figure 3.2     Announced job cuts in the bio/pharma industry (2000‐2007) 
Sources: Simon, 2007 
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suggested the weightiness of acquiring external R&D resources. 
To small-medium bio/pharma companies, the current condition is even tougher. 
Due to the credit crisis, banks have run out of lending money, hedge funds as well as 
private equity investors have shut up shop, and the public equity markets spiraled into a 
free fall. The barren financing resources have made it very hard for the biotech 
companies to run their business. A statistics from Biotechnology Industry Organization, 
Washington DC USA, shows that 180 quoted US biotech companies have less than one 
year’s cash in hand, and 120 of which have less than six months’ breathing space (as cited 
in Mitchell, 2009).  
In respect of the core competency of Big Pharmas is the unfailing supply of their 
pipelines, the current undervalued small-medium biotech companies provide the 
opportunities for Big Pharmas at bargain prices to acquire the external R&D facility. The 
recent sensational news of Roche’s (Switzerland-based Big Pharma) aggressive 
acquisition of Genentech indicated that the Big Pharma is thirsty for the biotech R&D. 
Through this large purchase of the biotech giant, Roche successfully expended its R&D 
territory to the biologics and also filled its pipeline (CTV News, 2009; Jucca & Cage, 
2009). Another example is that Johnson & Johnson (New Jersey, USA) acquired a New 
York- based bio/pharma company, Omrix, gaining access to the innovation of biosurgical 
and passive immunotherapy products at the year end of 2008 (Johnson & Johnson, 
November 2008; Carroll, 2008). Both cases show the Big Pharmas’ eagerness to build up 
the biotech part of their business. The frequent acquisition and merger also indicated that 
the external R&D is critical to strengthen Big Pharmas’ competitiveness. 
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3.1.2 Blockbusters’ Patent Protection has expired 
Besides the foresight of filling the pipelines, the major reason to obtain the 
external R&D innovation is that many splendid blockbusters have lost their patent 
protection recently, or will lose it soon (GlaxoSmithKline Inc., 2008). Lipitor, for 
example, the prescription of cardiovascular disease that brings Pfizer (New York, USA) 
billions of revenue every year, will lose its exclusivity in 2011. To meet this tough 
challenge, Pfizer has implemented a series of business restructuring, such as the purchase 
of Wyeth and the settlement with a generics manufacturer that produced and sold the 
generic vision of Lipitor (Pfizer Inc., 2008). Other Big Pharmas are also experiencing the 
intense pressures of the replacement of the million-dollar drugs with products of 
equivalent financial size. As a global leading pharma, Eli Lilly and Company (Indiana, 
USA) also faces the loss of market exclusivity of its best-selling drugs, such as Zyprexa 
and Cymbalta for neuroscience treatment and Gemzar for the treatment of non-small cell 
lung cancer (Eli Lilly and Company, 2008). In late 2008, Eli Lilly paid US$6.5 billion for 
ImClone Systems, a mid-size biotech with a colorectal cancer therapy called Erbitux. 
According to the Eli Lilly’s announcement, the acquisition of ImClone Systems would 
not only boost oncology pipeline with up to three promising targeted therapies in Phase 
III in 2009, but also bring in ERBITUX, a blockbuster targeted cancer therapy (Eli Lilly 
and Company , October 2008; Kennedy, 2008).  
3.1.3 The tendency toward personalized medicine 
Today, most physicians, even in the United States, still rely on the trial-and- error 
"standards of care" where the doctor makes a “most likely” diagnosis based on a patient’s 
symptoms and prescribes a drug or other treatment. Many drugs, particularly for mass-
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therapeutic option. For example, AstraZeneca (London, UK) had developed Entocort EC 
and launched it in the United States in 2001. Entocort EC is a drug with the efficacious 
treatment for the Irritable bowel syndrome (IBD), a hardly diagnosed gastro-intestinal 
disorder. With the high efficacy, the sales of the drug, however, were only US$25 million 
by 2003 (Wilmington, 2001). AstraZeneca then out-licensed the drug to Prometheus Labs, 
a San Diego-based specialty pharma. To improve the revenue of Entocort EC, 
Prometheus Labs did not expand its sales force for this drug; instead, the company 
developed an accurate diagnostic test to help physicians distinguish IBD from other 
similar diseases and largely promoted the diagnostic test. With the promise diagnostic, as 
well as the efficacy of the drug, Prometheus did not only achieve a much bigger sales 
number of Entocort EC, but because of the increasing demand, the company was also 
able to raise the average wholesale price of this drug by 66 percent upon traditional 
models. Figure 3.4 shows how the alliances between diagnostics and therapeutic areas 
improve the sales of drugs. As discussed above, the sales of Entocort EC was improved 
from 9% to 59% by the launch of IBD diagnostic test. The sales of Niaspan, a treatment 
of hypercholesterolemia, similarly, was increased twice by combined the selling of low 
density lipoprotein (LDL) subfractionization test. The MRI contrast agent also reformed 
the traditional trial-and-error practice and improved the diagnosis of multiple sclerosis 
(MS); as a result, Viveo, a treatment of MS, was projected to grow at 40% compared to 
7% projected increase in sales of its generics (Figure 3.4; Agarwal, 2009). 
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Thus, it shows that in the bio/pharma industry, outsourcing knowledge intensive 
activities to knowledge process organizations, such as CROs, serves a way to reduce 
innovation process obstacles. In the article named “Diffusing knowledge-based core 
competencies for leveraging innovation strategies”, Gupta et al. (2009) explore the 
relationship between bio/pharma companies and CROs, and then pointed out that 
multinational bio/pharma companies usually lose their core competencies over time and 
become dependent on CROs’ expertise, and that CROs obtain the opportunities of 
knowledge sharing and learning from their pharmaceutical company partners (Gupta, 
Woodside, Dubelaar, & Bradmore, 2009). 
3.2 The advantages & disadvantages of R&D alliances 
A number of factors have made it preferable for biotech companies to specialize in 
discrete elements of the product development pathway. As a result, bio/pharma 
companies need the consistent collaboration to acquire the complementary services, 
technologies to enhance the competitiveness. According to Deutsche BankAG estimates 
and company information (as cited in Mittra, 2007), an average of 30.5% of mid-late 
stage of R&D in the European bio/pharma sector was from external resources in 2004 
(Table 3.1). 
Table 3.1     Big Pharmas’ mid/late‐stage R&D pipelines  
Company  Phase II  Phase III  Filed 
Internal 
candidates 
External 
candidates 
% External 
GSK  34  4  5  31  12  28 
Sanofi‐Aventis  20  11  7  30  8  21 
Novartis  15  9  3  17  10  37 
Roche  9  4  10  13  10  43 
AstraZeneca  8  2  2  9  3  25 
Average  17.2  6  5.4  20  8.6  30.8 
Source: Mittra, 2007 
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3.2.1 Advantages of R&D alliances to bio/pharma firms 
While only the big M&A is most likely to jump to the front page of news, other 
types of transactions in the bio/pharma industry also show the various business strategies 
to capture and exploit new technologies and knowledge. Instead of the full-control over 
another company, licensing is the most common strategy for bio/pharma companies to 
reach the existing technologies and products from outside. As cited in Mirasol (2008), the 
Bio/Pharma R&D Statistics from PAREXEL, an U.S.-based pharmaceutical services 
group, showed that fully one third of the pipelines for the top 10 bio/pharma firms (by 
total numbers of products in development) comprised in-licensed products (Table 3.2).  
Table 3.2     The percentage of in‐licensed products in Biotech firms’ and Pharmas’ 
pipeline 
Company   % of pipeline in‐licensed 
Leading Biotech Companies by pipeline size (as of March 2008)  
Amgen (US)  
Genzyme (US)  
Genentech (US)  
25% 
33% 
50% 
Leading Pharma Companies by pipeline size (as of March 2008)  
GlaxoSmithKline (UK)  
Pfizer (US)  
Novartis (Switzerland)  
Merck (US)  
Roche (Switzerland)  
Johnson & Johnson (US)  
34% 
24% 
34% 
30% 
46% 
45% 
Source: PAREXEL as cited in Mirasol, 2008 
 
While the late-stage licensing agreements feed the short-term needs of the 
bio/pharma industry, such as bulking up pipelines or filling strategic gaps, to energize 
R&D and strengthen companies’ competitiveness in the long run, the early-stage drug 
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discovery collaboration is more fundamental. Moreover, R&D alliances provide 
alternatives with a degree of flexibility, cost advantage and/or risk-sharing to approach 
the external R&D expertise (Jones & Clifford, 2005).  
As many small bio/pharma companies and academia now have the abilities to 
identify and discover new drugs, Big Pharmas no longer monopolize the facilities and 
technologies. Therefore, through the proactive strategic alliances with bio/pharma 
companies, as well as academia, Big Pharmas could reinforce the upstream R&D 
innovation. GlaxoSmithKline Inc. (London, UK), for example, has cooperated with 
organizations such as Cellzome and the Harvard Stem Cell Institute to strengthen their 
early-stage R&D. In this 5-year, $25 million research agreement, GSK will fund research 
at the Harvard Stem Cell Institute (HSCI) and Harvard Medical School- affiliated 
hospitals, and support the annual basic research grants and staff exchange programs. The 
collaboration showed that both academia and pharmaceutical companies perceive the 
need of mutual dependence. Furthermore, GSK completed or expanded 21 new drug 
discovery alliances in 2007, adding significant breadth and scale to its R&D activities 
(GlaxoSmithKline Inc., 2008). By the same token, Pfizer, Novartis and AstraZeneca have 
strategically collaborated with the likes of the University of California in San Francisco, 
the Massachusetts Institute of Technology in Boston and Washington University in St. 
Louis (Huggett, 2008). As cited in Jones and Clifford, 2005, the data from Ernst & Young, 
one of the largest professional services firms in the world, shows the Pharma-biotech 
discovery alliance and acquisition highlights in 2005, where the most significant deals of 
bio-pharma were the AstraZeneca’s monoclonal antibody alliance with Cambridge 
Antibody Technology and the Pfizer’s US$480-million collaboration with Medarex 
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(Jones & Clifford, 2005). 
On the other hand, small-medium bio/pharma companies are usually resource- 
constrained -- they may afford the one- or two-year operations without further financial 
supports (Huggett, 2008). As mentioned above, many of the small-medium bio/pharma 
companies have experienced the tough condition of credit crisis where these companies 
are short for financial resources and even disfavored by the current stock markets. 
Therefore, rather than develop new R&D from scratch, the small-medium bio/pharma 
companies should focus on the individual relative strength and core competence, and 
collaborate with each other to achieve their goals more quickly and inexpensively than 
otherwise possible. In addition, by partnering with established companies, research-
intensive firms obtain the resources of marketing, distribution and sales, and thus gain the 
direct benefits. To stress the impact of small-medium firms’ alliance network on their 
early performance, Baum et al. (2000) analyze the horizontal alliances with other biotech 
firms and vertical alliances with pharmas and research institutes of 142 Canadian biotech 
companies. The result suggests that it is critical for small-medium firms to enhance their 
initial performance by establishing alliances, configuring them into an efficient network 
that provides access to diverse information and capabilities with minimum costs of 
redundancy, conflict, and complexity, and/or allying with established rivals that provide 
more opportunity for learning and less risk of intra- alliance rivalry (Baum, Calabrese, & 
Silverman, 2000).  
3.2.2 Disadvantages of R&D alliances to bio/pharma firms 
Despite their strong rationale and widespread use, strategic alliances are somehow 
unstable and have low success rates. The study named “Instabilities of strategic alliances: 
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An internal tensions perspective”, shows that only about half of the alliances are stable or 
achieve satisfactory performance (Das & Teng, 2000). As the strategic alliances are 
voluntary arrangements between firms to exchange and share knowledge as well as 
resources with the intent of developing processes, products, or services, the mutual 
understanding and compatibility between partners are crucial to the alliance performance. 
Past research has identified several factors that would affect alliance outcomes, such as 
goal congruence, inter-partner trust and conflict, flexibility in management, information 
exchange and firms’ prior alliance experience (Bleeke & Ernst, 1991; Glaister & Buckley, 
1998; Gulati, 1998; Hagedoom & Schakenraad, 1994; McCutchen Jr., Swamidass, & 
Teng, 2008; Stuart T. , 2000). In the article entitled “Minimizing leakage of value from 
R&D alliances”, Jones summarized the risks in alliance, and categorized the risks into 
four groups in terms of the impacts on financial, knowledge, reputation and strategic in 
the alliance life cycle. In Figure 3.8, the chart illustrates the risk factors and value leakage 
during the alliance life cycle (Jones, 2007).  At the beginning of alliances, the potential 
risks would result from how the deals are made, the communication with stakeholders 
and return on investment (ROI) assessment. During execution, the financial risks and 
companies’ reputation would become the major concerns to the management teams, such 
as the payment for milestones, the management of costs and overall performance, and the 
contractual disputes. The risks in the termination phase would involve the timing of 
termination that causes the loss of value or increases costs. Furthermore, the management 
of the partnership and the protection of intellectual property are the core of R&D 
collaboration and pose serious risks throughout the life cycle of strategic alliances (Figure 
3.8). 
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Unsurprisingly, the knowledge-driven sectors are usually centralized in those 
developed countries. Some studies about the R&D collaboration argue that these 
knowledge-intensive activities are usually highly geographical concentrated because 
geographical concentration of the relevant actors will facilitate the process of learning-
by-interacting, given the premise that innovation as an activity has become increasingly 
interactive and socially organized (Gertler & Levitte, 2005).  
In the case of biotechnology, this pattern of spatial concentration seemed to be 
strong and, if anything, becoming stronger rather than weaker over time. The most 
notable announcement in May 2002 that Novartis was moving its research operations to 
Cambridge, Massachusetts may be a good example for the argument of geographic 
concentration. According to industry analysts, the company’s decision to invest in 
Cambridge was motivated by the concentration of the life science expertise in the Boston 
area, such as the university and hospital researchers who are the key producers of 
potentially commercializable intellectual property, the rapidly growing biotech 
companies as potential partners in collaborative research, and the graduates from MIT 
and Harvard and other world-renowned institutions (Dyer, 2002).  
Access to venture capital (VC) is another key factor emerging from prior research 
on innovativeness and performance in biotechnology. Only the firms with sufficient 
access to ‘patient and knowledgeable’ capital who can recognize the special 
characteristics of bio/pharma industry, such as the large up-front costs associated with 
multi-year R&D processes followed by expensive regulatory reviews and trials, have the 
managerial and financial resources available to realize their innovation goals. Many 
literatures suggest that the geographical distribution of VC available for biotech firms is 
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also highly concentrated. In the article entitled “Signs of Life: The Growth of 
Biotechnology Centres in the United States”, Cortright & Mayer (2002) report that since 
1996, 75 percent of new VC investment in the USA has been located in the five largest 
biotech clusters, including Boston, San Francisco, San Diego, Seattle and Raleigh-
Durham. In a research about biotech firm-venture capital relationships, Powell, Koput, 
Bowie, & Smith-Doerr (2002) also find that over 50 percent of biotech firms receive local 
VC support. This phenomenon may be partly explained by the risky nature and lengthy 
time horizon of investments in bio/pharma companies: reaping the fruits of such 
investments may take years. Therefore, most of the studies about R&D collaboration in 
bio/pharma industry usually focus on the exchange of information, the joint sponsoring of 
research activities and the management of performance between the United States and the 
European Union, whereas very little information is available for the global spread of 
health biotech alliances and the extent to which the linkages cross the boundaries between 
developed and developing countries (Aguilar, Bochereau, & Matthiessen-Guyader, 2008; 
Melon, et al., 2009).  
In fact, however, the current trend of the gradual shift of global marketplace and 
business activities toward the developing world should not be ignored. In the article 
named “Pharma riding high?”, Stephen Burrill, CEO of Burrill & Co, a global life science 
industry-investing company, points out the current changes and pressures that bio/pharma 
companies have faced since the economic downturn in 2008. He then claims that the 
business models in this industry will evolve more virtually, and bio-clusters will move 
away from being geographic to being more globally built around diseases, pathways, 
markets and unique industry segments (Eisberg, 2009). In a study about spatial clustering 
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of economic activity and its relation to the spatiality of knowledge creation in various 
sorts of interactive learning processes, Bathelt et al. also question the merit of the 
prevailing explanatory model, where the realm of tacit knowledge transfer is confined to 
local milieus whereas codified knowledge may roam the globe almost frictionless. They 
argue that the co-existence of high levels of local knowledge transfer and many global 
“pipelines”, which are defined as the non-random remote connections, provides firms 
located in outward looking and lively clusters with a string of particular advantages not 
available to outsiders in the knowledge-intensive sectors such as bio/pharma (Bathelt, 
Malmberg, & Maskell, 2004). By conducting a national survey of biotechnology firms in 
Canada, Gerlter et al. also emphasize the importance of the interplay or balance between 
global and local forces and flows in this sector (Gertler & Levitte, 2005). 
As the global participation of life science discovery, the North American and 
European bio/pharma firms will not own the exclusive access to the drug discovery 
business any longer. While Big Pharmas still concentrate in the developed countries, a 
large number of small-medium bio/pharma companies are emerging in the rest of the 
world. Keeping in view of the low cost, the access to the regional resources and expertise, 
as well as the fast-growing markets, Melon, et al. (2009) conclude that in health biotech, 
substantial benefits are accrued from collaboration between firms in high-income 
(developed) and low- or middle- income (developing) countries. Therefore, the emerging 
market and the progressing R&D competence in the developing countries actually 
provide not only the opportunities of global business expansion but also the increasing 
competition to the bio/pharma firms that are rooted in the Western developed world. 
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Chapter 4 Strategic Alliances with Asian Bio/Pharma 
Companies 
As the credit crisis broke out in the United States, the global economic 
circumstances have seemed to be upside down -- the developed world becomes 
depending on the developing world, rather than the other way round. Two-thirds of the 
entire global economic growth last year was from the so-called emerging economies, 
which are predicted to grow at an average of 6.7% in 2008 compared with 1.3% in the 
United States, Japan and European Union (Cohen, 2008). In Asia, even though the 
economic growth rates of the biggest two countries, China and India, have also been 
hampered by the current global recession, over the past five years their economies have 
grown faster than economies anywhere else in the world.  
According to the recent worldwide economic forecasts that were conducted by 
Oxford Economics (Oxford, UK) , an economic forecasting consultancy, the future four-
year GDP values of Emerging Asia, China and India are twice as many as GDPs of the 
United States, Canada and the worldwide average, and four times GDPs of most countries 
in Europe (Figure 4.1; Oxford Economics, 2009). The impressive regional GDP in Asia 
shows the indisputable new market for global bio/pharma sector. The strong economy 
also suggests that the Asian countries’ have the abilities to not only become the biggest 
market of bio/pharma industry but also develop the advanced biotech R&D. 
In fact, the recent M&A among Big Pharmas also indicate their shifting attention 
to these emerging markets. Farkas et al., the partners of Bain & Company consulting firm 
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opportunities and threats to the companies that plan to build strategic partnership with 
those in Asia.  
4.1 Opportunities: 
4.1.1 Emerging marketplace & the driven bio/pharma industry 
Since decades ago, the rapid-growing economy in Asia has drawn attention of the 
developed countries to these emerging markets and the development of all kinds of 
industries in Asian countries. Among them, doubtless, China and India are the most 
attractive two in the developed world.  
Chinese Market 
In 2008, the GDP growth rate for country average of China is 9.8% and for 
industry sector is 49.2%. The incredible number made China listed as the number eight 
country with the fast economic growth in the world. However, despite the booming 
economy, the country did not put the equivalent effort into the national healthcare 
(Central Intelligence Agency, June 2009). According to the 2007/2008 Human 
Development Report, the Human Development Index, a measure of progress in 
healthcare, for China is 0.777, which gives the country a rank of 81st out of 177 countries 
with data (United Nations Development Programme, 2008).  
The rapid economy transformation in some way presents the Chinese government 
with a significant challenge in delivering equitable healthcare to its citizens, particularly 
the 10% living in poverty. On the other hand, China’s strong buying power also shows 
the potential of being the dazzling marketplace for the global pharmaceutical industry. 
Measured on a purchasing power parity (PPP) basis that adjusts for price differences, 
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China in 2008 stood as the second-largest economy in the world after the US, while in per 
capita terms the country is still lower middle-income (Central Intelligence Agency, June 
2009). In addition, the dramatically growing middle-class populations in China indicate 
the huge demand for resources from abroad. According to a McKinsey Global Institute 
analysis, by 2025, the urban middle-classes of China are expected to reach 612 million, 
increasing their spending fivefold to more than $2.3 trillion a year (Farrell, Gersch, & 
Stephenson, 2006).  
Indeed, several recent news and reports show that China’s health biotech market 
starts to take off. The growing market also had China actively developed the basic and 
applied biotechnology to participate into the global bio/pharmaceutical industry. From 
2000 to 2005, the bio/pharmaceutical sector in China grew 30% annually to $3 billion, 
compared with a 19% annual growth rate for its pharmaceutical industry as a whole, 
including the chemical medicine, the Traditional Chinese Medicine and biopharma (Jia, 
2007).  
India’s Market 
In India, another fast-developing country in Asia, the total consumer spending on 
healthcare products and services grew at a compounded annual rate of 14 per cent from 
2000 to 2005, driven by increasing affordability, shifting disease patterns and modest 
healthcare reform. The forecast of Indian pharmaceutical industry by McKinsey & Co. 
shows that on the basis of the market size of US$6.3 billion in 2005, the Indian 
pharmaceuticals market could reach a size of US$20 billion by 2015. This increase of 
market size implies a compounded annual growth rate of 12.3 percent, which is 
materially higher than the annual growth rate of 9 percent witness during 2000 to 2005. 
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The analysis also shows that if the Indian economy continues on its current high growth 
path, then the Indian pharmaceuticals market will triple to US$20 billion by 2015 and 
move into the world’s top-10 pharmaceuticals markets (Kumra, Mitra, & Pasricha, 2007). 
Like China, India has growing middle-class populations and strengthening 
purchasing power. Even though there is still one quarter of total population whose 
economic conditions are below the poverty line (defined by the Central Intelligence 
Agency, USA), the large numbers also represent great market opportunities for affordable 
health products (Melon, et al., 2009). 
Other Asian-Pacific Market 
Although China and India might represent the most attractive emerging markets, 
other Asian countries also contribute parts of the large pharmaceuticals market in the 
world. In the PwC’s report entitled “Gearing up for a Global Gravity Shift: Growth, Risk 
and Learning in the Asia Pharmaceutical Market,” a survey result shows that 55% of the 
interviewed multinational companies and 62% of Asian ones agree that the centre of 
gravity of the global pharmaceutical market is shifting from Europe and North America 
to Asia as a whole (PricewaterhouseCoopers, 2007).  
4.1.2 Financial Support 
The huge costs of sophisticated machines, well-trained workforces and advanced 
R&D programs, as well as distribution and marketing expenses, build the high barrier for 
new entries into the biopharmaceutical industry. On the other hand, the great demand for 
financial supports also makes companies out of this industry very quick, if the companies 
cannot get return very quick or find further funding. As a result, access to venture capital 
that provides investment capital and the entrepreneurial and managerial know-how 
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necessary for commercial success is another key successful factor to bio/pharma industry 
(Cooke, 2002; Powell, Koput, Bowie, & Smith-Doerr, 2002). 
In developed countries, where there are healthy systems of venture capital, 
industry estimates of the sources of capital for the first decade of a biotechnology 
company’s existence care that 10 per cent comes from venture capital and other private 
equity sources, 40 per cent from public markets, and 50 per cent from senior partners 
(Hess & Evangelista, 2003). As it has been discussed in previous sections, however, the 
current economic situations make many venture capitals and public markets reduce their 
interests in this risky and time-consuming industry.  
While the most of the public markets are relatively risk-averse in Asian 
developing countries, those governments actually provide many financial supports to 
establish the industry and to encourage private investments. Therefore, the political 
stimulants would be an essential element of bio/pharmaceutical industry in Asia. 
In the United States, as the global economic slump influences university 
endowments, industry R&D budgets, and philanthropic support worldwide, the focus is 
shifting to the role of government in sustaining the scientific enterprise. The entire 
Americans are currently eyeing President Obama’s $787 billion stimulus package to 
boost the U.S. economy. This package contains a $21.5 billion provision for funding 
scientific research and infrastructure: $10.4 billion for the US National Institutes of 
Health and $3 billion for the US National Science Foundation (Figure 4.2; Singh, 2009; 
Fox, 2009).  
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local governments dedicate funds to support the R&D in these organizations. The two 
major state funding programs that support biotech in particular are the National High 
Technology Research and Development Program of China, or the 863 Program, and the 
National Basic Research Program of China, or the 973 Program. The 863 Program 
focused largely on the commercialization of research results. The 863 Program allotted in 
2007, RMB 400 million (~ $52 million) to projects representing 11 priority biotech 
research areas, including product commercialization, gene therapy, and cell and 
immunotherapy for major epidemiological diseases. The 973 Program funds projects 
more focused on early-stage research, and grantees are expected to publish academic 
research papers on the supported work. Often, provincial and local governments will 
provide additional financial or other support, such as tax incentives or real estate space, to 
projects already funded by state grants, or vice versa (Ding, 2007; Partnering News, 
2009). For several decades, China’s central government has been encouraging basic 
research and patenting efforts, organizing the intellectual property into tangible assets for 
technology transfer (Frew, et al., 2008).  
In addition, the Chinese government also invests in quasi-venture capitali 
companies, such as Shanghai Venture Capital, to support start-up and growth companies, 
and attracted capital from the private sector into life sciences. In 2006, total VC 
investment in China grew by 22 % over 2005 to a total of approximately RMB 15 billion. 
Multinational investment accounted for nearly 76 % of this total. This is accomplished 
through tax incentives, preferential treatment, right of first refusal agreements on 
technologies from institutes and universities, and a number of other means. While the 
total value of all VC investments in China is actually considered small, the absolute 
                                                     
i quasi-public-private venture capital 
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number of VC investments into China’s biotech and pharmaceutical businesses is still 
increasing (Partnering News, 2009). 
Indian Government Funds & Policy 
While a large number of recent studies stressed the growing Indian market, few 
literatures report the government policy to develop the bio/pharmaceutical industry. As 
one of the biggest market in Asia, India government so far only has the first version of 
“millennium biotech policy” that was drafted in 2001. Recent news shows that the state 
government of Karnataka, whose capital - Bangalore is home for Indian biotech activity, 
is planning to release the revised ‘millennium biotech policy’ within a month. The 
revised policy aims “to give a number of incentives to the biotechnology industry,” said 
Katta Subramanya Naidu, minister for Information Technology and BioTechnology, and 
to attract more global investments into R&D in Indian biotech industry (Chennai & 
Bangalore, 2009). 
Taiwanese Government Funds & Policy 
In Taiwan, while there is no huge domestic market, biotech is one of the six 
emerging industries, such as biotechnology, green energy, medical care, quality 
agriculture, culture creative and tourism, specially selected by Taiwanese government for 
intensive development. To promote this industry, the government has announced the 
immediate launch of an US$1.76-billion “biotechnology takeoff package”, and 
encouraged venture capital funds as part of this comprehensive program. The program 
focuses on four major area, namely strengthening the industrial value chain and pre-
clinical development in the commercial process, establishing a biotechnology venture 
capital fund, promoting an integrated incubation mechanism, and creating the Taiwan 
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Food and Drug Administration (TFDA) so as to bring Taiwan’s medical device and 
pharmaceutical related regulatory environment to international standards. Taiwan is 
determined to lead Asia in genomic research, new drug development and human clinical 
trials supported by a vibrant and biotech- focused capital economy (Aldridge, 2009; 
Taiwanese Executive Yuan, 2009).  
Singaporean Government Funds & Policy 
Since the late 1990s when Singapore government decided to emphasize 
knowledge industries, including biomedical science, it has launched several biotech-
associated plans to build up world-class capabilities across the entire bio-pharmaceutical 
value chain. In 2000, the government launched a nearly US$2 billion, five-year the 
Biomedical Sciences (BMS) Initiative to the development of public and private sector 
biomedical research (Normile, 2007). On the heels of the initial BMS Initiative comes the 
Science and Technology 2010 Plan, announced in February 2006, which will commit 
another US$5 billion over five years toward bolstering public and private sector R&D. 
The plan focused on translational research with the hope of turning basic research 
discoveries into clinically useful and commercially viable products (Epps, 2006). 
In addition, aspiring to make biotechnology investment reach 3 percent of the 
country’s GDP, the Singapore government has launched numerous policies, such as tax 
incentives, research and training grants, preferential funding from venture capitals, to 
attract the investment from the US and European bio/pharmaceutical companies.  
As a result, Singapore has enjoyed phenomenal growth over the last four decades 
despite its small size and population of 4.4 million (UN Population Division). It has 
become recognized as a premier global hub in Asia for the manufacturing of 
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pharmaceuticals. It is now well-known the Singapore’s ambition to be the Biopolis of 
Asia -- a leading international biomedical sciences cluster advancing human health, 
through the pursuit of excellence in R&D activities, manufacturing and healthcare 
delivery. Indeed, considering the entire environmental circumstances, several Western 
bio/pharma companies have established centres of research teams or collaborated with 
Singaporean companies to work in markets in India and China. Leading companies like 
Aventis, GSK, MSD, Schering-Plough and American Home Product (AHP), have 
invested over US$1.3bn in plants to produce active pharmaceutical ingredients and 
finished products for worldwide markets (PricewaterhouseCoopers, 2007). 
4.1.3 Human Capital  
In a knowledge-intensive industry such as biotechnology, the most important 
input to the generation of successful new products is undoubtedly highly educated people 
(embodied knowledge). Therefore, it stands to reason that any analysis of innovation in 
biotechnology requires a strong focus on human resources and labour market practices.  
A key challenge faced by developing countries in trying to conduct basic research 
has resided in building basic scientific capacity. That has meant providing adequate 
funding for education and training and for constructing laboratories that could fulfil the 
needs of faculty and students alike. Today, these challenges remain stubbornly in place in 
many developing nations. Nevertheless, more and more developing countries have passed 
a threshold of basic competency and are now seeking to strengthen and broaden what has 
become a firm foundation in research. 
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Human Capital in China 
The expansion of biotech and pharma R&D in China has considerable 
implications for Chinese scientists. Historically, many Chinese students have gone to the 
West for advanced studies and in many cases stayed because of better opportunities for 
trained scientists. This phenomenon has changed recently. Because of the increasing visa 
restrictions in the West, especially the United States, agitation of mass layoffs, and on the 
other hand, the better career opportunities in China, not only more Chinese students 
choose to take the higher education, particularly in the life science field, domestically, but 
also more Western-trained Chinese scientists has been encouraged to go back to China. A 
scientist at Roche Australia, Edmund Tsuei said, quoted from the article of Can China’s 
supply of scientific talent keep up with demand, “There are many highly skilled, highly 
experienced and very successful scientists of Chinese origin working in North America 
and Western Europe wanting to return to their motherland to share their knowledge and 
experience and develop the next generation of scientists in their disciplines. With 
opportunities and incentives provided by both the government and private sectors, this is 
now possible (Wong G. , 2008).”  
Human Capital in India 
The Boston Consulting Group (BCG) describes how India is home to a large pool 
of well-trained, English-speaking scientists and managers (Wong, Bhalla, Goodall, Vaish, 
Wagner, & Janssens, 2006). In basic research part, India has world-class skills in 
chemistry and information technology. To replenish the domestic scientific human 
resources to jump-start the science-driven economic growth, several new initiatives have 
been launched, including the joint Department of Biotechnology (DBT)- Wellcome Trust 
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Biomedical Research Career Program, announced in September 2008. With a 5 year 
(2007 to 2012) budget of $1.5 billion, the DBT in New Delhi is India’s largest federal 
funding agency for the life sciences. One of their biotech-related programs that launched 
in 2008 is a 2 year, $6.5 million pilot program called the Biotechnology Industry 
Research & Development Assistance Program (BIRAP). Another one is a new 5 year, 
$75 million scheme called the Biotechnology Industry Partnership Program (BIPP) for 
the high-risk technologies and “breakthrough” research projects. This alliance will award 
40 early career fellowships to Indian citizens working in India or abroad (and possibly to 
non-Indian citizens who wish to pursue research in India), 20 intermediate fellowships, 
and 15 senior research fellowships annually, with the first awards to be handed out in 
May 2009. A major goal of this alliance is not only to woo Indian researchers working 
overseas to return to their home-land and to set up independent labs, but also to excite the 
biomedical research and bio/pharma industry in India (Singh, 2009).  
To encourage young people to think about science as a long-term career, Indian 
government has implemented some fellowship programs, such as the Young 
Entrepreneurs Scheme, a collaboration with the UK’s Biotechnology and Biological 
Sciences Research Council, and the Bio-design Program, a collaboration between 
Stanford University and the All India Institute of Medical Sciences in New Delhi. The 
Stanford Bio-design Program aims to train the next generation of medical technology 
innovators in areas such as diagnostics and imaging and has resulted in several patents. 
On the other hand, in November last year, Prime Minister Singh launched a 5 year $480 
million scholarship program for one million 10- to 15-year-old Indian students, whose 
funding will continue through graduate school as long as they pursue a science career. 
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This year, DBT will start an Ignition Grant scheme in collaboration with MIT to fund 
postgraduates, who have ideas that could lead to products but do not have a registered 
company or the infrastructure to put their ideas into action (Singh, 2009).  
In addition, since India has a large pool of treatment-naive patients, that is, those 
who have not taken any other medicine, it would be a good opportunity for India to train 
medical professionals to conduct clinical researches. Global consulting firm McKinsey 
(as cited in Iype, 2004) also estimates that by 2010 there will be 700,000 specialty 
hospital beds and 221 medical colleges in India. Combined with the modern 
infrastructure in technology and transportation, as well as its various types of diseases, 
India would be a hot bed to conduct non-core clinical trial activities on a broad spectrum 
of drugs for many multinational bio/pharmaceutical firms. 
Human Capital in Taiwan 
Over the past two decades, Taiwan has concentrated on the development of high-
tech industries such as electronics, information technology, computer and semiconductors. 
Through the example of the Silicon Valley and the Bay Biotech Cluster in San Francisco, 
California, Taiwanese government attempted to integrate the innovative success in high-
tech industry and the vigorous biomedical research to revolutionize the bio-pharma 
industry in Taiwan (Efendioglu, 2006). Currently, Taiwan has 164 universities with more 
than 80 incubation centres within the campuses; 18 medical centres; a growing number of 
science-based industrial parks; and government and private non-profit research institutes 
such as Academia Sinica, the Development Centre for Biotechnology (DCB), the 
Industrial Technology Research Institute (ITRI), and the National Health Research 
Institute (NHRI), all of which are involved in biotech-related research activities. The 
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main strengths of Taiwanese bio-pharma industry are the energetic basic research in life 
science and the sound system of clinical trials. According to the recent statistic from 
Ranking Web of World Research Centers, Academia Sinica (the Taiwanese National 
Academies) lists as the 16th of Top 2000 Global R&D Institutes and as top one in Asia 
(Ranking Web of World Research Centers, 2009). To build up the foundation of 
biotechnology and cultivate young scientists in Taiwan, Academia Sinica and National 
Health Research Institutes (the Taiwanese Institutes of Health) not only has frequently 
collaborated with the domestic preeminent universities, such as National Taiwan 
University, National Yang Ming University and National Tsing Hua University, but also 
established the Taiwan International Graduate Program to attract young talents from other 
Asian countries and worldwide (Scholarshipnet, 2008). In addition, Academia Sinica has 
held regular Academician Convocations to keep the tight connection with the science 
societies in other countries, particularly in the United States, Japan and China (Academia 
Sinica, 2009). 
Research articles published in the peer-reviewed international scientific and 
technical journals represent quantifiable research outputs of academic research institutes. 
According to the statistics, the number of papers that were published in SCI/SSCI 
Journals by National Taiwan University has been increased over seven times during the 
past three decades (Chen, 2008). In addition, as shown in Table 4.1, the 189,337 filed 
patents from 1995 to 2005 makes Taiwan list as number nine of the top innovative 
countries in the world, and following Japan and Korea as the third among Asian counties 
(Table 4.1; Liu & Lin, 2009). “Innovation in biotechnology here is growing, but the 
challenge is to connect the local with the global,” says Chung-Cheng Liu, general director 
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of Biomedical Engineering Research Laboratories (BEL) in Taipei, the largest non-profit 
R&D organization in Taiwan and part of the Industrial Technology Research Institute (as 
cited Aldridge, 2009). 
Table 4.1     World’s most innovative countries by the number of patent submission and 
approvalii 
Rank 
(Patent no.)  Country  Patent submission Patent approval Approval rate 
1  Japan  5,218,096 2,067,674 39.63% 
2  United States  2,850,957 1,467,758 51.48% 
3  Korea  1,044,868 381,344 36.50% 
4  Taiwan  252,777 189,337 74.90% 
5  Israel  49,885 18,494 37.07% 
6  Ireland  18,411 7,561 41.07% 
7  Singapore  9,414 3,809 40.46% 
Source: Science & Technology Policy Research and Information Centre, NHRI, Taiwan; 
as cited in Liu & Lin, 2009. 
 
 
Besides the intense basic research of life science, Taiwan also owns a pool of 
well-trained medical professionals. Coupled with the first-class healthcare quality and a 
large number of patients (because Taiwanese patients prefer large-scale hospitals), 
medical professions usually can conduct quality clinical researches efficiently. The well-
developed medical systems also ensure the safety and quality of clinical researches that 
are conducted in Taiwan. In the study about the clinical trials in Asian countries, Taiwan, 
Singapore, Hong Kong and South Korea are listed as tier two, whereas India, China and 
Southeast Asia are tier three. The report shows that the quality standards for clinical trials 
in Taiwan adhere to the accepted international standards of International Conference on 
                                                     
ii Including United States Patent and Trademark Office (USPTO), Japan Patent Office (JPO) and State 
Intellectual Property Office of the P.R.C. (SIPO) 
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Harmonization/ WHO Good Clinical Practice (ICH/GCP). GCP guidelines has been 
implemented by Taiwanese Department of Health since 1997 and then further revised in 
2002 to be consistent with ICH standards. THE DOH conducts GCP inspections on 
nearly all clinical trials to ensure their quality and credibility and is equivalent to the FDA. 
Taiwan also offers the option of Joint Institutional Review Board Approval (JIRB), which 
allows for multi-centre approval as opposed to individual IRB approval for each hospital. 
More than 40 hospitals have participated in the joint IRB, and JIRB has helped Taiwan 
attract more multi-centre trials (Drug Delivery, 2007). The clinical trials reviewed by the 
DOH in 2002 were shown in Table 4.2. The proportion of multinational trials in Taiwan 
is 49.79% (71/143) in 2002. Taiwan has demonstrated its ability to conduct increasing 
number of early phase clinical trials and to participate in multi-national clinical trials. 
These efforts are essential in creating a favourable environment for domestic research and 
development of new pharmaceuticals (Wang & Chen, 2005). 
Table 4.2     Multinational and domestic clinical trials reviewed by Taiwanese DOH in 
2002 
 Multinational trials Domestic trials Total 
Phase I 0 4 4 
 Phase II 12 14 26 
Phase III 52 49 101 
Phase IV 7 5 12 
Total 71 72 143 
Source: Wang & Chen, 2005 
 
 
Human Capital in Singapore 
As the full government supports and vigorous foreign investment, Singapore is 
now a city of imported scientific talents -- currently about one third of all scientists in 
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Singapore are foreigners (Epps, 2006). With this advantage, Singapore has developed 
strong connection with the first-class university and research institutes in the world. In 
addition, to maintain a critical mass of scientists, as well as to breed its own scientific 
workforce, the government has revamped the education system -- from overhauling the 
primary school curriculum to offering scholarship programs that fund undergraduate and 
Ph.D. science training either locally or abroad. As a result, the National University of 
Singapore was ranked as the 30th out of top 100 universities in the world last year, and 
following the other three universities in Japan and Hong Kong as the fourth in Asia (QS 
Top University, 2008). 
Because of the sound healthcare system, Singapore is also viewed as a good 
location for conducting clinical trials in Asia. It owns high-quality medical facilities and 
highly educated doctors, many of whom went to school in the United States or Europe, 
especially England. Therefore, it is listed as the tier two of Asian countries for conducting 
clinical researches. However, one of the drawbacks of doing clinical trials there is its 
small population (about 4.3 million people), and thus sometimes trials in Singapore can 
encounter difficulty recruiting enough patients (Drug Delivery, 2007). 
4.1.4 Expertise in regional diseases 
In addition to the prevalent studies of cancer therapies, developing countries have 
been increasing their expertise in this field and possess other resources, such as 
indigenous materials, important for health biotech development (Melon, et al., 2009). 
Hepatitis B and C, for example, has caused epidemics in parts of Asia and Africa, and it 
is endemic in China. Therefore, several hepatitis research centres in Asia countries have 
fruitful discovery in both basic pathology and clinical therapy. Taiwan, for example, has 
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dedicated itself in study of hepatitis for a long time and fostered many outstanding 
academic and clinical research talents for studies of liver disease. Aiming to stand in a 
key position as a ruling research centre for liver diseases, Taiwanese government is 
integrating both excellent academic results & industrial strength in Taiwan with 
international research institutes & drug firms related in liver diseases. Genelabs 
Technologies Inc. (NASDAQ:GNLB), for example, announced the collaboration on 
hepatitis C research with Taiwan National Health Research Institutes and Genovate 
Biotechnology Co., a biopharmaceutical company in Taiwan (San Jose Business Journal, 
2008). 
Another example is Tuberculosis (TB), which distributes not uniformly among the 
world. About 80% of the population in many Asian and African countries testing positive 
in tuberculin tests, while only 5-10% of the US population test positive. While one third 
of the world's current population has been infected with Mycobacterium tuberculosis, the 
pathogenic virus of TB, most of these cases will not develop the full-blown disease; 
asymptomatic, latent infection is most common. As a result, it is estimated that the US 
has 25,000 new cases of tuberculosis each year, 40% of which occur in immigrants from 
countries where tuberculosis is endemic (Kumer, Abbas, Fausto, & Mitchell, 2007). To 
ensure the widespread availability of affordable, faster and better TB drug regimens that 
will advance global health and prosperity, the TB Alliance, a global non-profit 
organization, was formally launched in October 2000, at the International Conference on 
Health Research for Development, in Bangkok, Thailand.  
The TB Alliance is operated as a product development partnership (PDP), 
working to develop new, simpler, faster-acting TB treatments. As less than three percent 
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of global funding for health R&D is dedicated to diseases of the developing world, such 
as TB, it is unlikely for a pharmaceutical company (even a Big Pharma) to develop drugs 
by itself. However, through partnering globally with the public, private, academic, and 
philanthropic sectors, the TB Alliance functions as a virtual R&D organization, 
minimizing costs, and optimizing the speed of drug development. Over the past decade, 
global health PDPs, like the TB Alliance, have advanced dozens of potential new 
diagnostics, drugs, vaccines, and microbicides through the development pipeline, toward 
registration and launch. Recent news also shows that many global pharmaceutical 
companies, such as Tibotec Inc. (Tibotec), have collaborated with TB Alliance to identify 
new compounds for the treatment of TB, and on the other hand, to gain the access to the 
vast developing market (TB Alliance, 2009). 
4.1.5 Low-cost 
It is not a new challenge for multinational companies that competition from 
generics and pricing pressures in the healthcare market continue to create pressures for 
reduction in costs in all parts of the pharmaceutical value chain. “Cost has always been a 
driver of outsourcing decision,” says Mike Keech, director of PwC’s advisory services 
group in the pharmaceutical and life science sector (Drakulich & Arnum, 2009). As a 
result, outsourcing to lower cost but highly effective companies in Asia has become a 
common response to these pressures. For example, generics make up the majority of 
China’s biopharmaceutical market, accounting for >90% of the $3 billion market in 2006. 
China’s population size creates a significant need for low-cost products. For both 
multinational and domestic generics producers, China’s low-cost manufacturing, huge 
work force and less stringent regulation have been the major elements that make 
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are on par with those of the United States and Western Europe. As the comparison shown 
in Figure 4.3, the cost of PhD full time equivalent in the United State was about ten times 
in China, five times in Taiwan, and three times in Singapore; the price of typical project 
in the United States is five times in China and about two times in Taiwan and Singapore. 
Recent news also shows that pharmaceutical companies outsource the clinical research or 
set up clinical R&D centres in Asia countries, such as Singapore and Taiwan.  
4.2 Threats: 
4.2.1 Safety and quality of products 
Although the low-cost production, a pool of scientific talent and maturing public 
infrastructure make Asian countries become more important in the pharmaceutical supply 
chain, one of the major concerns to Western bio/pharma companies is the safety and 
quality of products. 
One key event was that Baxter International (Deerfield, IL) recalled thousands of 
vials blood-thinner heparin that has been linked to hundreds of allergic reactions and 
possibly 81 deaths in the United States. Baxter and FDA later traced contamination 
(oversulfated chondroitin sulfate) to the product’s active pharmaceutical ingredient (API), 
which was supply by Scientific Protein Laboratories’ Changzhou SPL plant in 
Changzhou City, China (Freking, 2009). The FDA has increased inspections and product 
testing efforts in response to the melamine contamination problem which originated in 
Chinese dairy products, such as flavoured drinks, milk and milk-based products in China. 
The widespread contamination made several Taiwanese food producers recalled a large 
number of products (U.S. Food and Drug Administration, 2008). 
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At the beginning of this year, the FDA announced that the Paonta Sahib facility 
owned by India-based Ranbaxy Laboratories falsified data and test results in approved 
and pending drug applications. In fact, since the fall 2008, the FDA has issued two 
warning letters and instituted an Import Alert barring the entry of all finished drug 
products and active pharmaceutical ingredients from three Ranbaxy's facilities, including 
Dewas, Paonta Sahib and Batamandi Unit facilities, due to violations of U.S. current 
Good Manufacturing Practices requirements. That action barred the commercial 
importation of 30 different generic drugs into the United States and remains in effect (U.S. 
Food and Drug Administration, 2009). 
Because of the recent events, many Western bio/pharmas state that some Asian 
manufacturing is no longer as profitable to the companies as it used to be, even though 
the cost could be reduced to 50-60% by doing so (Drakulich & Arnum, 2009). As a 
global Big Pharma, Pfizer emphasizes that adherence to quality standards are a 
prerequisite for working with any supplier. By further asked the questions about the 
consideration to the suppliers in India and China in a recent interview with 
Pharmaceutical Technology, Natale S. Riccardi, the president of Pfizer Global 
Manufacturing and senior vice-president of Pfizer, said, “Special considerations when 
working with suppliers in emerging markets are numerous, obviously the first and 
foremost is product integrity and safety. Any potential supplier is evaluated on its ability 
to produce material in a manner that is fully compliant in all regulatory procedures,” as 
cited in Ricciardi (2008). 
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4.2.2 Intellectual property right 
Intellectual property protection is essential for bio/pharma industry because while 
the cost of innovation is high, the cost of imitation is relatively low. Unlike commodity-
based industries, where access to cheap materials, labour, or markets can provide a 
competitive advantage, knowledge- and innovation-based industries, such as commercial 
biotechnology, rely on the ability to generate and exploit knowledge to gain a competitive 
advantage. Intellectual property protection therefore plays an integral role in enabling 
bio-pharma research by establishing a barrier to competition that permits pioneers to 
sustain lengthy research efforts and recoup their R&D costs. That is to say, to get a drug 
to market, a pharmaceutical company needs at least three pieces of intellectual property -- 
one is for the target, one is for the product, and one is for the manufacturing process 
(Friedman, 2006, pp. 79-106). 
Government incentives fuel the growth of bio-pharma industry in Asia countries, 
but intellectual property risk remains a concern to many of Western pharmaceutical 
companies. By interviewing with 93 senior pharmaceutical executives from multinational 
companies with operations across nine different territories in the region, including China, 
India, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam, 
PricewaterhouseCoopers (PwC) report that three-quarters of interviewers said they are 
worried about intellectual property rights and legal risks, and concerns about intellectual 
property protections are cited by them as the biggest reason to consider leaving Asia 
countries (Schooler, 2007). 
However, since the awareness that assurance of intellectual property rights 
protection has been an important incentive for multinational companies’ investments, 
many Asian countries have recently introduced rules ensuring greater protection to 
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intellectual property rights, in compliance with World Trade Organization (WTO)’s 
Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS; Thomas, 
2008). In the same survey that was conducted by PwC, it is also highlighted that nearly 
the same amount (74 percent) of multinational companies saw an improvement in 
intellectual property right protections during the past five years, primarily as a result of 
the introduction of new intellectual property laws, underpinned by a stronger government 
emphasis on intellectual property protection and more rigorous application of existing 
laws (Schooler, 2007). 
4.2.3 Political, social and economic stability 
In pursuit of business opportunities in developing countries, the biggest challenge 
to executives is the uncertainty and security of economic environment. Indeed, national 
security is a critical factor that determines the level of investment, both domestic and 
foreign, along with favourable business environment, positive policy matrix and return on 
investment. Global investors apply these parameters diligently while making their 
decision on investment destinations. 
In the case of Asian countries, political turbulence is usually the major influence 
of financial markets. Taiwan’s stock market, for example, generally responds 
dramatically to new information regarding political decisions that may affect domestic 
and foreign policy. However, because of the complicated relationship between Taiwan 
and China, and, regretfully, the democratic reform of Taiwan, the political condition in 
Taiwan has been restless all along. In a recent study about the congressional effect 
between the pre- and post- democratization on the stock market, Wang and Lin (2009) 
show that the congressional effect and the democratic effect are negative on stock returns, 
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and the democratic effect even increases the volatility of stock market. Considering both 
the slippery investment market, many Western companies show the indifference toward 
the bio/pharma industry in Taiwan. On the contrary, the tranquil political condition in 
Singapore indeed has drawn many Western pharmas’ favour. 
Because the series of conflicts between India and Pakistan since 1947, India was 
the focus of numerous attacks from both externally based terrorist organizations and 
internally- based separatist or terrorist entities, said the State Department’s annual report 
on global terrorism (Kumar, 2009). The 2008 Mumbai attacks devastated India’s 
financial capital and its largest city, and made India become one of world’s most 
terrorism- afflicted countries. As a result, the business confidence that was weakening 
due to current global turmoil will now bear the heat of this terror attack, with sentiments 
further going weak. As to the bio/pharma industry, where the quality and safety of 
products is the essence of the business, terror attacks caused several Western companies 
to rethink their strategies in India (Drakulich & Arnum, 2009). 
4.2.4 Distance & Business transparency 
Considering the requirement of the unobstructed communication and business 
transparency to build mutual trust, distance would be a critical threat to performance of 
strategic alliances between Western and Asian bio/pharma firms. Distance between two 
countries can manifest itself along four basic dimensions: cultural, administrative, 
geographic and economic. The types of distance influence different businesses in 
different ways. In the case of R&D collaboration between Western and Asian bio/pharma 
companies, geographic and cultural distance is most likely to disrupt the mutual 
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understanding and the transparency of management, and thus affect the efficiency and 
productivity of the collaborated activities.  
Geographic distance 
In general, geographic distance affects the costs of transportation and 
communications, so it is of particular importance to companies whose cooperation 
requires a high degree of coordination among highly dispersed people or activities. This 
is one of the reasons why bio/pharma companies form as local clusters. 
However, as the modern information and communication technologies are 
developed, it becomes easier to connect disseminated R&D activities and thus makes 
distributed R&D organization possible (Howells, 1990). More importantly, as I discussed 
above, both the market and R&D skills of biopharmaceutical industry are globalizing. 
Companies that pursue business opportunities from emerging markets should balance 
between the risk of geographic distance and the possibility of profit. 
Cultural distance 
A country’s cultural attributes determine how people interact with one another and 
with companies and institutes. Differences in religious beliefs, race, social norms and 
language are all capable of creating distance between two countries. Indeed, they can 
have a huge impact on trade: All other things being equal, trade between countries that 
share a language, for example, will be three times greater than between countries without 
a common language.  
Moreover, the study also shows that colony-colonizer links between countries 
boost trade by 900%, which is perhaps not too surprise given Britain’s continuing ties 
with its former colonies in the commonwealth. As a result, because of the greater 
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predominance of English as second language and the stronger historical links with the 
UK, Singapore, India, Hong-Kong may collaborate more with developed countries. 
Through the globalization and the development of Westernizing education systems, the 
barrier of language is getting lower. In the article entitled “Biotech Vision Taiwan”, for 
example, Cyranoski (2003) reports that Western researchers generally find that Taiwan’s 
research environment fosters a fruitful, open exchange of ideas in which language is not a 
problem. In everyday life, too, English works well enough at supermarkets and hospitals 
for researchers and their families to feel comfortable without having to learn Chinese. 
4.3 Opportunity & threat analysis of strategic alliances with firms in China, 
India, Singapore and Taiwan 
While the North American and European bio/pharma industry has been developed 
for several decades, the sector is just newborn in Asia. In light of the regional growing 
market, several Asian governments have actively promoted the bio/pharma sector, 
providing considerable sum of financial and administrative support to cultivate the human 
resources in basic research and clinical R&D and improve research facilities and 
technical infrastructure.  In addition, they have heavily invested biotech-related business 
and offered special tax incentives to foreign bio/pharma firms to bridge the Western-
Asian R&D alliances. In the previous sections, I detail the biotech-encouraging policy 
and financial programs and identified the potential risks in four Asian countries: the two 
biggest countries -- China and India, and two biotech-capable countries -- Singapore and 
Taiwan -- and provide the comprehensive view of Asian bio/pharma industry. Figure 4.4 
presents the opportunity and threat analysis of Western bio/pharmas’ strategic alliances 
with firms in these Asian countries from the following aspects: size of domestic market, 
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government support, quality of human capital and healthcare, innovative ability, expertise 
in local diseases, cost, safety and quality of products, protection of intellectual property, 
political, social and economic stability, bio/pharma related regulation and infrastructure, 
cultural familiarity and business transparency. 
 
 
Figure 4.4      Opportunity and threat analysis of Western bio/pharmas’ strategic 
alliances with firms in China, India, Singapore and Taiwan 
 
 
The distinct strength and weakness of these countries provide various options of 
collaboration for Western bio/pharma companies. Generally speaking, the considerable 
strength of China and India is the immense marketplace and the low-cost labours and 
facilities, whereas the strength of Singapore and Taiwan would be the soft skills, 
infrastructure and regulations. In the study entitled “Strategies and achievement of 
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bioscience industry development in Israel, Ireland and Singapore”, Liu and Lin (2009) 
analyze the competitiveness of bio/pharma sectors in China, India, Singapore and South 
Korea, and also suggest that while Taiwan and Singapore do not have the advantages of 
marketplace and cost benefits, other circumstances, such as the healthcare quality, 
regulations and infrastructure, actually make these two small countries a better 
environment of biotech industry than China and India. Considering the functional 
difference in each phase of drug development process, as well as the strength and 
weakness of these countries, Western bio/pharma companies have the opportunities to 
find partners with proper function to reinforce their core strategies and avoid the potential 
risks. As shown in Table 4.3, I categorize the types of collaboration in terms of the 
different specialties of these countries. Manufacturing small-molecule drugs, for example, 
needs less technique or R&D and the cost would be the major concern to bio/pharma 
companies. Thus, as long as Western companies establish optimal quality control systems, 
it would be most profitable by collaborating with manufacturers in China and India. 
However, manufacturing biotech drugs requires advanced R&D and strict control for the 
quality and safety of products. Therefore, Singapore and Taiwan would have better 
performance of manufacturing biotech drugs. Bearing in mind that clinical trials require a 
large number of volunteers and competent healthcare systems, Taiwan could offer great 
profit to Western bio/pharma partners by conducting high-quality clinical research. The 
requirement of collaboration in basic research is stringent, especially in terms of 
intellectual property right, innovation and expertise of local diseases. However, 
considering that the advanced life science is still concentrated in North America and 
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European, Western bio/pharma firms could only benefit from the collaboration of local 
disease study.  
 
 
Table 4.3     The options of Western bio/pharma companies’ collaboration with firms 
China, India, Singapore and Taiwan in terms of countries’ specialtiesiii 
Countries 
Collaboration 
China  India  Singapore  Taiwan 
Manufacture of small‐
molecular drugs 
5  5  1  2.5 
Manufacture of biotech drugs  3  3  4.5  4 
Clinical trials  2  2  4  4.5 
Basic research  3  3.5  3.5  3.5 
 
 
                                                     
iii On a scale of 1 (poor) to 5 (excellent) 
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Chapter 5 Conclusion 
In respect of the rising concerns in health care and the matchless significance of 
medicine, many countries have heavily invested the bio/pharma industry. Through the 
introduction of the value chain from drug discovery to FDA approval, it is evident that 
the steady exchange of knowledge and technology for companies are essential to run 
business in the bio/pharma sector, regardless of the companies’ economic scale. The 
constant interchange of R&D resources motivates companies’ strategic alliances in the 
bio/pharma industry. This report concludes four factors that encourage companies to 
build partnership: 1) the fulfilment of the early-stage pipeline by external R&D recourses; 
2) the reducing financial resource from the expired blockbuster drugs; 3) the tendency 
toward personalized medicine; 4) the rising hurdle of FDA examination. 
While the complex nature of bio/pharma business, as well as the growing global 
market and competition, make strategic alliances an essential element of bio/pharma 
firms’ productivity and competitiveness, the partnerships do not always give company 
equivalent payoffs. This report further discusses about how bio/pharma firms manage the 
different transactions to acquire external resources and analyses the advantages and 
disadvantages of strategic alliances, providing a comprehensive view to the bio/pharma 
firms that are seeking external resources to sustain their business. Moreover, in light of 
the globalizing bio/pharma industry, a conceptual framework is applied in this report to 
illustrate the motives of strategic alliances in the broader circumstances (p. 36). 
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Unlike the United States with widening budget deficit, many Asian countries are 
actively investing bio/pharma industry. The cases of the bio/pharma sectors in some 
Asian countries (China, India, Singapore and Taiwan) analyzed in Chapter 4 reveal that 
Western bio/pharma firms should think over the R&D alliances with those in Asian. The 
result shows that in addition to the immense Asian market and low cost, which are 
definitely the most important factors, those countries have provided substantial financial 
resources and biotech developing plans to support their domestic bio/pharma sectors. In 
addition, as the capability of life science knowledge and R&D is progressing in Asia, the 
larger pool of scientific talents and advanced facilities also provides Western bio/pharma 
firms opportunities of strategic alliances. On the other hand, the potential risks in these 
Asian countries and the problems caused by remote collaboration should also be taken 
into consideration. The risks include the product safety issues, the protection of 
intellectual property, the stability of business environment and the business transparency 
resulting from geographic and cultural distance. Finally, this report analyzes the 
opportunities and threats of Western bio/pharmas’ strategic alliances with firms in these 
Asian countries and provides the detailed comparison of countries’ specialty to 
companies that look for collaboration in different stages of drug development process. 
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